ADVANCED ORAL GEL PLATFORM
WATER-FREE, MUCOADHESIVE ORAL-HEALTH TECHNOLOGY
WATER-FREE. SALIVA-ACTIVATED.
ACS Biomed is developing a differentiated oral-health platform designed around an anhydrous formulation architecture that progressively hydrates upon contact with saliva. The platform is being explored through two technological configurations designed for different industrial and commercial strategies.
- Product family
- 2 development configurations
- Status
- In development
- Seeking
- Industrial and distribution partners
THE ORAL MUCOSA IS A DIFFICULT ENVIRONMENT.
The oral cavity combines constant moisture, continuous salivary turnover and mechanical movement. Together these conditions rapidly reduce how long a locally applied formulation stays where it was placed.
For functional components this is a delivery problem rather than a dose problem: the development challenge is maintaining contact with the mucosa long enough for the formulation to perform its technical role.
The context in figures.
Epidemiological context for the oral-health area. Not evidence of product efficacy.
People worldwide affected by oral diseases.
WHO, Oral health, Fact Sheet, 17 March 2025People affected by untreated dental caries.
WHO, Global Oral Health Status Report, 2022FROM ANHYDROUS TO MUCOADHESIVE FILM.
The platform rationale is one of delivery: start from a water-free system and use saliva as the trigger for hydration.
- THE PROBLEM
Contact time is the critical variable
Salivary turnover and movement shorten how long a formulation remains on the oral mucosa. Without residence, the technical contribution of functional components stays limited in time.
- THE MECHANISM
Progressive hydration triggered by saliva
An anhydrous carrier remains stable before application and hydrates progressively on contact with saliva. That change of state is the phase in which the polymer system develops its mucoadhesive characteristics.
- THE FORMULATION ANSWER
Water-free carrier and mucoadhesive polymers
The concept combines a water-free carrier system with mucoadhesive polymers, designed to form a film on the mucosa and improve the residence of the components it carries. Final formulation under development.
- Global burden of oral diseasesWHO. Oral health. Fact sheet. 2025.
- Untreated dental caries: global prevalenceWHO. Global Oral Health Status Report. 2022.
- Lactoferrin: properties documented in the literatureReference under validation
- Mucoadhesive polymers and residence on the oral mucosaReference under validation
- Oral microbiome modulation: probiotics and postbioticsReference under validation
- Precision fermentation for recombinant proteinsReference under validation
The epidemiological references describe the context of the therapeutic area. Literature on individual components is not evidence of finished-product efficacy: no study has been conducted on the ACS formulation, which remains under development.
WATER-FREE, SALIVA-ACTIVATED DELIVERY.
The platform is being developed around an anhydrous oral-gel architecture designed to remain stable before application and progressively hydrate when exposed to saliva.
Parameters such as water activity, residence time and stability window remain development parameters until experimentally confirmed, and are not published.
ONE PLATFORM. TWO TECHNOLOGICAL PATHWAYS.
Both configurations share the anhydrous, mucoadhesive architecture but follow different industrial and commercial strategies. Both are under development.
STANDARD
Designed around established ingredient technologies with a view to efficient industrial development and professional oral-health positioning.
- Bovine lactoferrin in liposomal / microencapsulated form
- Anhydrous vegetable glycerin
- Saccharomyces boulardii
- Lactobacillus rhamnosus SP1
- Postbiotic components
- Optional K-B0399® depending on final formulation
- Sodium hyaluronate
- Hybrid mucoadhesive polymer system
- Colloidal silica as rheological / manufacturing aid
- Lactoferrin
- Bovine
- Delivery
- Liposomal / microencapsulated
- Animal-derived
- Yes — contains milk-derived lactoferrin
- Dairy-free
- No
- Positioning
- Established ingredient pathway
- Status
- In development
VEGAN / PRECISION FERMENTATION
A biotechnology-driven development configuration exploring recombinant lactoferrin and precision-fermentation technology for premium international market positioning.
- Recombinant human lactoferrin produced through precision fermentation
- Beta-cyclodextrin-based inclusion / delivery concept
- Saccharomyces boulardii
- Lactobacillus rhamnosus SP1
- Postbiotic components
- Animal-free development strategy where technically confirmed
- Lactoferrin
- Recombinant / precision fermentation
- Delivery
- Beta-cyclodextrin-based
- Animal-derived
- Designed to be animal-free
- Dairy-free
- Target positioning, subject to final formula verification
- Positioning
- Advanced biotechnology pathway
- Status
- In development
The Standard configuration contains milk-derived lactoferrin and is not described as vegan or dairy-free. For the Vegan / Precision Fermentation configuration, vegan, dairy-free and Halal compatibility will be stated only once technically and regulatorily verified. No regulatory approval is guaranteed.
MICROBIOME-FOCUSED ORAL CARE.
The development concept may include the components below. Not every candidate will necessarily appear in the final commercial product: final formulation under development.
Probiotic yeast included among the candidates in the formulation concept.
Probiotic strain under evaluation within the platform.
Postbiotic components under evaluation within the concept.
Inclusion subject to the final formulation.
MUCOADHESIVE ORAL PROTECTION.
The rationale is physical and delivery-led: supporting hydration and residence on the oral mucosa through film formation.
A component that supports hydration within the formulation system.
Designed to form a protective film on the oral mucosa.
The shift out of the anhydrous state happens on contact with saliva.
Designed to improve residence on the oral mucosa and support its comfort.
DEVELOPMENT FORMAT.
Single-dose oral gel in stick-pack. Protective single-dose packaging under development.
- Portability
- Hygienic unit dose
- Controlled format
- Practical international distribution
PARTNERSHIP OPPORTUNITIES.
The platform enters the oral-health area through a technological approach — anhydrous, mucoadhesive delivery — rather than as another reference in the category.
Two technological configurations allow distinct industrial and market strategies to be built from a single formulation architecture.
- Distribution
- Licensing
- Commercial partnership
- Industrial partnership
ACS Biomed is evaluating selected international distribution, commercial and industrial partnerships across its expanding Consumer Health portfolio.
LET’S DISCUSS THE PLATFORM FOR YOUR MARKET.
ACS Biomed is evaluating industrial, licensing and distribution partnerships for selected territories.
- Via Vincenzo Manzini 21
- 33100 Udine, Italy
- info@acsbiomed.com
- www.acsbiomed.com
- Tel. 0432 1714549